Treatment of Fever with Unani medicine Cap Mubarak

Phase 3

• Conditions: Health Condition 1: R509- Fever, unspecified

• Registration Number: CTRI/2024/01/061859
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM New Delhi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Participants of either sex in the age group 18 to 65 years.

2. History of onset of fever within 24 hr.

3. Participants with oral temperature 100 F- 102 F presenting with any of the following symptoms:

Fever

Headache

Body ache

Joints pain

Shivering

Chills

Palpitation

Skin Flushing

Exclusion Criteria

1. Intake of any antipyretic drugs in the previous 8 hrs.

2. Participant having oral temperature of greater than 102 F.

3. Known high risk clinical conditions such as pneumonia, sepsis, dengue haemorrhagic fever,meningitis, hepatitis B, etc.

4. Known cases of Immuno-compromised clinical conditions such as HIV, cancer etc.

5. Known cases of other clinically significant co-morbid conditions (severe hepatic, renal, cardiovascular disorders, etc.) that in the opinion of the investigator could affect the efficacy and safety outcome of the study.

6. Thrombocytopenia i.e. absolute platelet count below 1,00,000.

7. Known hypersensitivity to study drug or any of its ingredients.

8. Pregnant and Lactating females.

9. Diabetes Mellitus or any systemic disorder requiring prolonged treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The efficacy of the study drug in the treatment of Humma (fever) will be assessed on the basis of reduction in the symptoms and change in temperature from baseline to end of the study and the achievement of defervescence,Timepoint: At baseline and on 3rd day

Secondary Outcome Measures

Name	Time	Method
Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examination.Timepoint: At baseline and end of treatment i.e. 3rd day.